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To understand better the molecular and cellular events associated with status epilepticus, a
multifaceted analysis has begun on hippocampal tissues therapeutically removed from patients
with temporal lobe epilepsy. In this first study, quantitative changes in major ganglioside species
are reported, as well as the immunocytochemical localization on the ganglioside GD3 in epileptic
human hippocampus. Although significant variations were found between patients, the pattern of
change wasconsistent when compared to normal values obtained from an autopsied specimenand
the literature. Total ganglioside content was reduced in epileptic hippocampi, which was
attributable, in part, topyramidal cell loss found in CAl and CA3. In each case, the percentage of
ganglioside GD3 was increased significantly, while ganglioside GD1. decreased. The former change
is probably associated with reactive astrocytosis and the latter with loss of neuronal dendrites.
Immunocytochemical localization revealed GD3 in the stratum radiatum and the subgranular
layer of the dentate gyrus. In these areas, GD3 was present in punctate structures and astrocytes.
These findings indicate that GD3 increases in selected areas of the sclerotic hippocampus and is
presumably related to localized accumulation of reactive glial cells. Since gangliosides have a
high affinity for calcium and localized increase in extracellular calcium could disrupt normal
neuronal function, the localized increase in GD3 may not only denote reactive glial cells but may
contribute directly to the altered, hyperexcitable condition ofepilepsy.
INTRODUCTION
Epilepsy is a major debilitating disease ofthe central nervous system (CNS) which
is characterized by synchronized neuronal discharges [1]. Despite intensive research
efforts, the cellular and molecular basis ofepilepsy remains uncertain. We have begun
a multifaceted analysis of human hippocampal tissue obtained from patients with
electrically characterized temporal lobe epilepsy. By determining the biochemical and
morphological features that characterize human epileptic tissue, we hope to identify
the key factors that are responsible for promoting the hyperexcitable state. One
possible factor is the glycolipid components ofcell membranes.
Gangliosides are a family of sialic acid-containing glycolipids that are enriched in
neuronal membranes [2-4]. These molecules participate in numerous cellular phenom-
ena, e.g., growth, adhesion, membrane excitability, and functional interactions [5-7].
Numerous studies have shown that the relative amount of individual species of brain
gangliosides is a direct indication of the structure, number, and types of neural
membranes [8-10]. For example, GDla is associated with synaptic membrane densities
[11-13]. Likewise, changes in ganglioside composition accompanypathological altera-
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tions in neural tissues. For example, GD3 is often found in high concentrations in
traumatized CNS tissue and is considered a marker for reactive glia in many
neurological diseases [10,12,14,15,16]. Hence, an examination of gangliosides can
provide important information on the health and cellular composition ofbrain tissue.
Studies from our laboratory [17-19] and the laboratories of others [20,21] have
revealed significant ganglioside changes in various animal models of experimentally
induced seizures. These changes reflect, to some extent, the pathological changes that
are associated with epileptic brain. In humans as well as in animals, these pathological
changes frequently involve neuronal loss and gliosis. In the hippocampus of an
epileptic, this is referred to as "hippocampal sclerosis," which is characterized by
gliosis and loss of neurons in the Sommer sector and end folium (Rose's area HI and
H3-5) [22-25].
One principal aim of the present study was to examine changes in ganglioside GD3.
We have previously shown that GD3 is closely associated with reactive, but not resting,
glial cells [10,16,26,27]. In addition, GD3 is associated with a number ofcells, such as
Muller glial cells [15], undifferentiated neurons [14,28], and malignant transformed
cells [29], which share a common property in being metabolically active. We have
hypothesized that the membranes of these cells must be highly permeable to ions and
metabolites [10,27]. Hence, reactive glial cells may have fundamental significance in
regulating the extracellular environment in epileptogenesis [30]. To test this hypothe-
sis, our first objective in this study was to test for the presence ofGD3-positive glia and
determine their tissue distribution. The availability of brain tissue from human
patients offers a unique opportunity to correlate the biochemical and immunohisto-
chemical changes in ganglioside distribution that are associated with electrophysiolog-
ically and clinically defined epileptic tissue.
MATERIALS AND METHODS
Brain Tissues
Hippocampal gyri from epileptic patients were removed en bloc during surgery, and
quickly cut into transverse slabs 1-2 cm wide. Individual specimens were either frozen
on dry ice or fixed by immersion in 0.1 M phosphate buffer containing 2 percent
formaldehyde. Frozen tissue slabs were used for both quantitative ganglioside analysis
and immunocytochemical localization of GD3 on immediately adjacent tissue. Since
histological preservation in fresh-frozen tissue is relatively poor, quickly fixed tissue
was also examined by immunocytochemistry.
A normal control hippocampus was obtained with permission from a 26-year-old
male who died suddenly with no known neurological symptoms. Comparable slabs of
hippocampal tissue were obtained after autopsy and frozen on dry ice within 16 hours
ofdeath. Since gangliosides are relatively stable afterdeath, the results ofquantitative
analysis were considered reliable. Immunocytochemical study was limited to fresh-
frozen tissue from the hippocampus and was used only for comparative localization.
Ganglioside Quantitation
The amount of major gangliosides within samples was determined by methods
described in detail elsewhere [31].. Briefly, a ganglioside-enriched fraction was
obtained from each sample after chloroform/methanol extraction and DEAE column
chromatography. Individual gangliosides were separated by thin-layer chromatogra-
phy (TLC) [32], visualized by resorcinol, and quantitated with a densitometer.
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Immunocytochemical Localization
To correlate biochemical analysis with immunocytochemical localization, fresh-
frozen samples were first sectioned and the remaining adjacent tissue processed for
ganglioside quantitation. Frozen specimens were sectioned on a cryotome (10 ,um),
mounted on glass cover slips coated with poly-l-lysine, and allowed to air dry for one
hour. Sections were fixed in 0.1 M phosphate buffered saline (PBS), containing 4
percent formaldehyde for five minutes, and rinsed with PBS containing 0.3 percent
gelatin. All subsequent steps were performed in PBS with gelatin.
Monoclonal antibody R24 was provided by Dr. K.O. Lloyd, Sloan-Kettering
Institute, New York, and has known specificity for GD3 [33]. Polyclonal rabbit
antibody against purified human glial fibrillary acidic protein (GFAP) was provided
and characterized by Dr. L.F. Eng, Stanford University, Palo Alto, California. These
primary antibodies were diluted 1:75 for anti-GD3 and 1:300 for anti-GFAP and
applied to sections for 20 minutes. After rinsing, sections were incubated for 20
minutes in peroxidase-conjugated secondary antibody. Anti-GD3 was localized with
goat anti-mouse IgG (Sigma) diluted 1:40, and anti-GFAP was localized with goat
anti-rabbit IgG (Cappel), diluted 1:300.
Formaldehyde-fixed tissues were postfixed by immersion in 5 percent acrolein in
phosphate buffer (PB) for one hour and sectioned on a vibrotome (50 ,um). Sections
were incubated in PB with 0.03 percent Triton-X100 for one hour, rinsed, and treated
to block nonspecific stain. Sections were reacted at room temperature in the following
reagents in PB at room temperature and rinsed after each step: 1 percent borohydride
for ten minutes, 0.2 percent lysine and 0.1 percent gelatin for one hour, and 4 percent
goat serum for 2-24 hours. Sections were incubated for 48 hours at 40C with anti-GD3
diluted 1:200 or anti-GFAP diluted 1:600. After rinsing, sections were incubated for
48 hours with thecomplementary secondary antibodies diluted threefold more than for
frozen cryotome sections. Peroxidase activity was visualized with diaminobenzidine/
H202.
The quantitative ganglioside analysis and immunocytochemical studies were per-
formed and evaluated independently in order to prevent bias.
RESULTS
Ganglioside Quantitation
The study was divided into two phases. In the initial phase, full transverse slabs of
fresh-frozen tissue containing the entire hippocampal formation were assayed for
ganglioside distribution. Four specimens from epileptic patients were assayed. The
pattern ofgangliosides separated on a TLC plate and treated with resorcinol is shown
in Fig. 1. Quantitative results shown in Table 1 reveal significant differences between
patients in the percentage ofGD3.
Immunocytochemical localization ofGD3 in adjacent sections showed corresponding
qualitative differences in the intensity ofstain between specimens. Thegeneral pattern
ofstain, however, was similar in each case. Within the CA sub-regions, stain was most
pronounced near the zones ofpyramidal cell loss. The Sommer's sector regionofCA1
showed at least partial loss of pyramidal cells in all cases (see Figs. 2,4A,6A), and
typically was most heavily stained (see Figs. 3,4). Within CA2 and CA3, relatively less
pyramidal cell loss was evident, and stain was less dense. By comparison, nopyramidal
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G FIG. 1. Thin-layer chromatogram of
extracted gangliosides from hippo-
D 1 a ~~~~~~~~~~~~campi of epileptic patients (1-3) and
standard sample (Std). Each lane con-
tained about gsg of sialic acid. The
plate was developed with chloroform/
Gn' 1 | l _ * l ll l l l l ll | wmethanol/0.02
percent CaC12 (55:45:10).
Gangliosides were visualized with resor-
cinol-HCI agent. GD3 (*) is identified as
twocloselyspaced bandsbetweenGMland
GDI.- Note the sample from Patient 2 has
Xii 1.1 .1. 1. II 131 11 | relatively GD3 (arrows) compared to
other samples. Twospecimens were avail-
PatientStd:IA able from Patient 1, anterior (IA) and
posterior (IP) portions.
cell loss was apparent in the prosubiculum, and no stain was detected above
background.
Based on these findings, hippocampal specimens from a second set of patients were
prepared for ganglioside quantitation. As shown in Fig. 2, the CA1 region was
dissected into two approximately equal areas. The area designated "A" coincides with
the region associated with the most common pyramidal cell loss (Sommer's sector).
The area designated "B" was immediately adjacent and may include part of the
prosubiculum where neuronal loss was less pronounced. Hippocampi from two patients
and one normal autopsy were thus analyzed, and the results are shown in Table 2. The
most striking differences were in the percentages ofGD3. In A and B regions from the
normal control, GD3 was 2.9 percent. By comparison, GD3 was significantly higher in
region A than region B in the two patients. This difference corresponds to the location
of the pyramidal cell loss which was distinct in region A of both patients, but not
apparent in region B.
In addition to GD3, other consistent changes were evident in the ganglioside content
TABLE 1
Gangliosides from Hippocampus of Epilepsy Patients
Patient
1(P) 1(A) 2 3
Total SA (Ag/gdw) 1,902 1,077 1,037 909
GMI 17.1 12.6 19.8 11.0
GD3 5.4 6.1 13.6 7.7
GDla 32.0 35.1 23.8 31.8
GD2 5.2 5.5 4.6 4.9
GDlb 19.1 18.3 15.3 20.0
GTIb 18.0 22.5 22.9 24.6
Gangliosides shown as percentage of total for each sample. Total sialic acid (SA) expressed as
micrograms per gram dry weight. Samples from anterior (A) and posterior (P) regions of Patient 1
shown.
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UK; 1."', ~~~~~~FIG. 2. Micrograph of transverse
section of hippocampus from Patient 5
which shows typical pyramidal cell loss
in Sommer's sector. Two sub-regions of
Ammon's horn which were assayed for
ganglioside content are illustrated. Re-
gion A includes Sommer's sector, and
region B is the adjacent region with less
pyramidal cell death. Arrows point to
,1 presumptive pyramidal cell layer. Den-
tate granule cell layer D. Bar = 2 mm.
of hippocampal tissue from epileptic patients (refer to Tables 1 and 2). The level of
GDlawas markedly lower in patient tissues and was inversely related to the level ofGD3.
GM, appeared to decrease moderately. The percentages of GD2, GDMb, and GT1b were
moderately elevated. Total ganglioside content within the tissue was markedly
decreased in epileptic tissues. Most of these changes were noticeably evident in
comparing sub-regions A and B from the two epileptic patients.
Immunocytochemical Localization
Based on immunocytochemical study of all patients' and control tissues, the
distribution of GD3 associated with epilepsy was determined at the light microscopic
level. In sections of patients' hippocampi, the overall intensity of GD3 immunoperoxi-
dase stain varied from indistinct background levels to heavy localized deposits of
reactivity. These qualitative variations correlated directly with the quantitative
difference in GD3 levels determined by biochemical assay. Nodistinct stain was evident
in hippocampus from normal tissue, and only moderate stain was present in sections
TABLE 2
Gangliosides from CAI Region
Epilepsy Patient
Normal 4 5
TissueRegion A B A B A B
Total SA (gg/gdw) 2,127 2,705 1,133 1,684 1,642 2,046
GM, 26.8 24.4 20.8 26.6 22.4 22.5
GD3 2.9 2.9 9.6 4.3 4.4 2.8
GDla 41.2 43.2 26.9 28.7 29.1 34.6
GD2 2.1 2.2 4.2 4.8 2.1 2.4
GDIb 10.4 10.1 14.0 15.0 14.6 13.7
GTIb 11.6 11.8 15.7 12.8 17.2 15.9
Gangliosides shown as percentage of total for each sample. Location of regions "A" and "B" are
illustrated in Fig. 2. Total sialic acid (SA) expressed as micrograms per gram dry weight.
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FIG. 3. Micrographs showing local-
ization of GD3 in rapidly fixed human
*_ ;'xl_ _BLAZ_A hippocampus. Control section (CNT)
- J W '. : t ><>xB e~->;a!a*<w - . x*4; ^ shows background and endogenous per-
CNT -2--^*J ~tg,, 7 - :; oxidase activity in blood vessels. Spe-
cific stain is found in the subgranular
layer (SGL) of the dentate (D). Apical
dendrites of pyramidal cells (arrows)
{; 0 . | are seen in relief in CA2 due to specific
stain in the stratum radiatum (SR). No
;s 2; -- u jgzt pyramidal cells are seen in this region
~~~~~~ ~~~~ ofCAl. Bar = 1mm.
from patients with low levels of GD3 increase. In cases of major increases of GD3, a
distinct and characteristic immunostaining pattern was evident. Since the immunocy-
tochemical localization and quantitative analyses were performed independently with
blind controls, these results indicated that the immunocytochemical localization
method reliably reflects the changes in GD3 associated with the epileptic tissue.
Whether the endogenous GD3 present in normal hippocampus may be masked to
immunodetection or distributed relatively uniformly was not determined.
Despite the variation in stain intensity, a consistent pattern of localization was
observed. In most cases, dense immunoperoxidase stain was localized in the subgranu-
lar layer (SGL) ofthe dentate and in parts ofthe stratum radiatum (SR) (Figs. 3 and
4). Lighter stain was apparent in adjacent regions of the stratum moleculare (SM).
Within these regions, immunodetectable GD3 appeared in small, broadly scattered,
punctate structures and in stellate cells that were identified by location, shape, and size
as astrocytes (Fig. 5).
FIG. 4. Micrographs of
sx adjacent fresh-frozen sec-
1.41Y.. tions showing comparable
A ~~~~~~~~~~~areas ofCAI fromPatient2. .~~~~ ~~~.... ~~~~~Total pyramidal cell (P) loss
r ~~~~~~~~:in CAl and major gaps (ar-
rows) in granular cell layer
2 .Wr<e;+ ~ t s<0!|| - l 1 |l ll l l-i of dentate (D). Immuno-
F5$ w>ljrtbv; ;e*T2>-1| 2l|1 |i|peroxidase stain for GD3 densely labels stratum radia-
*.t _ A tum (SR) and subgranular
layer (SGL). Bar = 0.5 mm.
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FIG.*5.Higher magnification micro-
graph showing cellular localization of
~~~~~ ~~~GD3 in stratum radiatum of CAI. Spe-
cific reaction product is distributed in
puncta scattered throughout tissue and
appears to accumulate in astrocytes
(arrows). Bar = 40,um.
Astrocytes stained by anti-GFAP were found throughout normal hippocampal
tissue in patterns distinct for each area. Forexample, stellate astrocytes were located in
the stratum moleculare (Fig. 6D). Within the dentate layer, cell bodies of large
astrocytes were located in the subgranular layer, and many oftheir processes extended
into the granule cell layer. In areas of neuronal loss, a massive increase in GFAP-
positive processes was found (Fig. 6). The dense matrix ofastrocytic processes in these
sclerotic areas obscured the identification and morphology of individual astrocytes.
Areas of astrocyte proliferation coincided in large part with the distribution of GD3
associated with epilepsy (Fig. 6).
DISCUSSION
The present study shows that increased levels of GD3 are present within localized
regions of the hippocampal formation of epileptic patients. The amount of GD3 varied
widely between patients and is correlated in part with the degree of pyramidal cell
death. Immunocytochemically detectable GD3 is seen in dispersed punctate structures
and associated with astrocytes. These findings support previous studies which indicate
that GD3 is associated with neural degeneration and accompanying gliosis [28].
One important question is whether the localized increase ofGD3 is a consequence or,
rather, a causative factor of epilepsy. It is known that GD3, as a divalent anionic
glycolipid, binds calcium with high affinity [34,35]. An abnormal accumulation ofGD3
in neural membranes may increase the local concentration of extracellular calcium,
thereby altering a variety ofcritical homeostatic balances, and promote a hyperexcita-
ble state. Based on the present positive finding, further experiments are being
conducted on kindled cats as an experimental model. Initial results show an accumula-
tion ofGD3 in similar regions ofthe experimentally induced "epileptic" cat hippocam-
pus [Holly JA, et al: unpublished results].
Other questions arising from this study include the ultrastructural distribution of
GD3 in normal and epileptic hippocampi. If GD3 is involved in promoting neuronal
hyperexcitability, then it should be distributed in association with neuronal mem-
branes. The GD3-positive punctate structures in epileptic tissue are similar in size to
focal synapses and may represent astrocytic processes coveringjunctional contacts.
Also unknown is the distribution of GD3 in the normal hippocampus. In the normal
human hippocampus assayed, GD3 was 2.9 percent of the gangliosides. Despite thisYU ET AL.
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substantial level ofGD3 in normal tissue, immunocytochemical localization revealed no
distinct stain above background. Similarly, other immunocytochemical studies of GD3
localization have been unable to show distinct localization in the adult brain of mice,
despite its known biochemical presence [28,36]. GD3 has been shown to accumulate in
the plasma membrane ofoligodendrocytes during development [37]. Perhaps endoge-
nous GD3 in normal adult tissue is masked from immunodetection.
The majority ofimmunodetectable GD3 associated with epilepsy was localized in two
zones: the stratum radiatum of CAI, and the subgranular layer of the dentate.
Neuronal death accompanying epilepsy is most common in CA1 and was clearly
associated with increased levels of GD3 in this region. However, in most cases of
epilepsy, relatively little neuronal death is found in the dentate granule cell layer or in
CA4, which border the subgranular layer [22-25]. And yet, without substantial local
neuronal death, the subgranular layer had increased levels of GD3. Thus, GD3
accumulation within the hippocampus of epileptics may signify more than simply the
presence ofreactive astrocytes in zones ofneuronal degeneration.
It is tempting to suggest that many forms ofepilepsy arecaused by an initial trauma
leading to the generation of reactive astrocytes and accumulation of GD3. The high
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affinity of GD3 for calcium results in excessive calcium-dependent neural activities,
which may include increases in transmitter release and protein phosphorylation. A
cycle of neuronal hyperactivity and death followed by proliferation of GD3-positive
reactive glia may perpetuate the cycle.
Although speculative, this scheme is consistent with several lines of morphological
and physiological evidence regarding temporal lobe epilepsy. Special attention is
directed to thesubgranular layerofthedentate whereGD3 increases have been found in
both epileptic human and kindled cat hippocampi. The dentate granule cells supply a
major excitatory input into the hippocampus, the Schaffer collaterals, which have long
been considered a primary candidate in promoting hippocampal hyperexcitability
[38]. A dense layer of astrocytic cell bodies is present in the subgranular layer, and
many oftheir processes are in close proximity to granule cell bodies and axons [39,40].
It is known that the principal neural transmitter ofgranule cells is glutamate, and that
pharmacological agents which blockglutamate activity inhibit ictal activity [41,42]. In
addition, the injection of glutamate has been shown to cause neuronal death and
gliosis, which is typical of epileptic hippocampal sclerosis [43]. Calcium has been
implicated in epileptogenesis [44,45], and certain anticonvulsant drugs inhibit calci-
um-dependent protein phosphorylation [46]. Notably, Ca/calmodulin-dependent pro-
tein kinase is localized preferentially in the hippocampus and appears particularly
abundant in the dentate [47]. In vitro experiments have shown that gangliosides can
enhance Ca++/calmodulin protein phosphorylation [48]. In conjunction with this
process, long-term changes occur in Ca++/calmodulin phosphorylation activity of
kindled rat hippocampi [49]. The present results support this scheme, although other
interpretations are possible. Future experiments, such as localized injections of GD3,
are planned to test the proposed GD3 mechanisms ofepilepsy directly.
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